Lack of Knowledge, Social Stigma Are Leading to Rise in HIV Infections

November 21, 2018

WELLESLEY, Mass., Nov 21, 2018 – Underestimating the risk of contracting the virus, lack of knowledge, and social stigma have led to a rise in HIV infections. In turn, educational campaigns to counter stigma and discrimination have increased. A new BCC Research study projects that by 2023, the global market for HIV diagnostics and therapeutics will be worth $27.1 billion.

Key strategies for effective HIV management include early diagnosis, rapid initiation of antiretroviral therapy, and viral load monitoring. Existing HIV therapies fail to address long-term adverse effects and effectiveness against drug-resistant HIV strains. From an estimated $22.0 billion in 2018, a five-year compound annual growth rate of 4.3% is projected, according to a newly updated report by BCC Research Diagnostics and Therapeutics for HIV: Global Markets.

The HIV diagnostics market is segmented into three major test types: antigen and antibody-based tests, CD4 tests and viral load tests. The antigen and antibody-based test segment is projected to hold a 55.3% share of the market in 2023.

Research Highlights

  • The HIV pipeline is dominated by high-cost, oral, branded specialty medications. Only a few newly approved drugs are forecast to capture a leading share of the market.
  • North America holds 46.2% of the global market for HIV therapeutics. Properly set regulations and reimbursement by healthcare insurance are drivers of growth in this region.
  • Among test types, viral load testing is the fastest-growing segment, expected to expand by 9.7% during the forecast period.

“An increase in screening and awareness programs has raised the overall number of people getting tested for HIV,” the report notes. “To tackle the HIV/AIDS epidemic, several countries have initiated free diagnostic testing, mobile HIV/AIDS testing, HIV testing counseling and awareness programs in school.”

Single-Tablet Regimen Is Increasing In Popularity

The single-tablet regimen fixed-dose combination segment currently accounts for 36.2% of the global HIV therapeutics market; increased patient compliance has made this the preferred therapy for HIV. Fixed-dose combinations are increasingly preferred because they reduce dosing errors and lower the likelihood of the HIV virus becoming drug resistant. This class will grow by 4.9% to 2023, reaching $10.1 billion.

Editors/reporters requesting analyst interviews should contact Eric Surber at

Diagnostics and Therapeutics for HIV: Global Markets( PHM058C )
Publish Date: Oct 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.